(Q44292432)

1 December 2017

1 reference

title

Role of linezolid in antimicrobial therapy (English)

1 reference

1 December 2017

1 reference

Pedro-Manuel Carmona

1

1 reference

1 December 2017

Eva Romá

2

1 reference

1 December 2017

Emilio Monte

3

1 reference

1 December 2017

Javier García

4

1 reference

1 December 2017

Miguel Gobernado

5

1 reference

1 December 2017

language of work or name

Spanish

0 references

publication date

1 January 2003

1 reference

Infectious Diseases and Clinical Microbiology

1 December 2017

published in

1 reference

1 December 2017

volume

21

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

30-41

1 reference

Problems and current solutions for the treatment of infections caused by gram-positive microorganisms

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Implications of vancomycin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

1 reference

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activities of linezolid against multiple Nocardia species

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Post-antibiotic growth suppression of linezolid against Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid therapy of Staphylococcus aureus experimental osteomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Efficacy of linezolid in a staphylococcal endocarditis rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Successful treatment of disseminated Mycobacterium chelonae infection with linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid: an oxazolidinone antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Oxazolidinones: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid: a new antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid for the treatment of resistant gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Thrombocytopenia associated with linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid-Induced anemia and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid--a review of the first oxazolidinone

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Linezolid and reversible myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2803%2972872-9

7 January 2021

10.1016/S0213-005X(03)72872-9

Identifiers

DOI

1 reference

1 December 2017

1 reference